# ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer

> **NCT00242762** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 36 (—)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** ZD1839 (IRESSA™)
- **DRUG:** Docetaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00242762
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2006-03
- **Final completion:** 2006-03
- **Target enrollment:** 36 (—)
- **Last updated:** 2011-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00242762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00242762, "ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00242762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*